Why not prescribe the best drugs for XXXX now?

@entity1 @entity137 @entity1289 @entity101 @entity102
As Westernised societies have become more affluent, the attitudes of the population have become more risk-aware. @entity1 are now intolerant of small risks as well as the physical or mental discomforts from @entity137 . Safety and tolerability are now major forces driving the development of new medicines for the treatment of @entity102 and the prevention of increasingly rare events. For example, over the past decades, lower and lower treatment thresholds have been recommended in @entity101 . Public perception of risk strongly influences the acceptability of lifetime treatment, especially for mild @entity101 . This era has also witnessed great advances in the development of antihypertensive drugs that combine efficacy with unsurpassed tolerability. However, the philosophy of Scottish teachers of Materia medica still appears to be followed-'never be the first or the last to prescribe a new drug'. @entity1289 ( @entity1289 ) inhibitors and angiotensin II receptor antagonists are as safe and as efficacious as other antihypertensive medications and better tolerated. Large trials (HOT, HOPE, UKPDS and PROGRESS) point to the need for rigorous control of blood pressure particularly in high-risk individuals. Antihypertensive drugs that act on the renin-angiotensin system will probably impact significantly on achieving optimal blood pressure levels. Should it not now be accepted that high-risk @entity1 should have @entity1289 inhibitors and angiotensin II receptor antagonists prescribed as first-line agents? We review the evidence for the use of @entity1289 inhibitors and angiotensin II receptor antagonists as antihypertensive agents.
